Perceptive Advisors’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-10,794,876
Closed -$441M – 127
2024
Q2
$441M Hold
10,794,876
– – 10.63% 1
2024
Q1
$456M Sell
10,794,876
-170,317
-2% -$7.15M 7.98% 1
2023
Q4
$465M Buy
10,965,193
+876,808
+9% +$25.2M 10.38% 1
2023
Q3
$220M Hold
10,088,385
– – 7.35% 2
2023
Q2
$321M Buy
10,088,385
+3,576,658
+55% +$110M 9.28% 2
2023
Q1
$159M Hold
6,511,727
– – 4.69% 4
2022
Q4
$205M Hold
6,511,727
– – 5.77% 4
2022
Q3
$184M Buy
6,511,727
+1,425,000
+28% +$42.4M 5.34% 3
2022
Q2
$134M Hold
5,086,727
– – 4.21% 4
2022
Q1
$178M Hold
5,086,727
– – 3.7% 7
2021
Q4
$165M Hold
5,086,727
– – 2.54% 10
2021
Q3
$150M Buy
5,086,727
+443,632
+10% +$12.5M 2.18% 11
2021
Q2
$119M Hold
4,643,095
– – 1.54% 18
2021
Q1
$63.7M Buy
4,643,095
+99,033
+2% +$1.45M 0.81% 32
2020
Q4
$75.3M Buy
+4,544,062
New +$59M 0.81% 35

Other funds holding CERE

Perceptive Advisors's CERE Position: Q3 2024 in Review

Perceptive Advisors sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2024, closing a stake of 10,794,876 shares — an estimated $441M sold.

Perceptive Advisors first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $465M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Perceptive Advisors reported no remaining Cerevel Therapeutics Holdings position as of Q3 2024 after selling out during the quarter.
  • Perceptive Advisors sold 10,794,876 Cerevel Therapeutics Holdings shares in Q3 2024, an estimated $441M.
  • Perceptive Advisors first reported a position in Cerevel Therapeutics Holdings in Q4 2020 and held it in 15 quarters.
  • Perceptive Advisors's Cerevel Therapeutics Holdings position peaked at $465M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2024.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.